Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1999 Jan;90(1):93–100. doi: 10.1111/j.1349-7006.1999.tb00671.x

Wide Spectrum of Antitumor Activity of a Neutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor

Makoto Asano 1,✉, Ayako Yukita 1, Hideo Suzuki 1
PMCID: PMC5925977  PMID: 10076571

Abstract

Vascular endothelial growth factor (VEGF) is known as an angiogenic factor for tumor angiogene—sis. We developed a neutralizing anti—VEGF monoclonal antibody (MAb), MV833, and examined its antitumor activity against 27 human tumor cell lines transplanted in nude mice. All the tumor cell lines used in this study secreted various amounts of VEGF into culture medium in vitro. However, the growth of the cell lines, including three which expressed VEGF receptor, was not affected by exogenously added MV833 in vitro. All tumor cell lines including colon, lung, breast, pancreas, and melanoma, grew subcutaneously in nude mice. The growth of HeLa/v5, which had been transformed by human VEGF121 gene and secreted large amounts of VEGF, was significantly faster than that of the control vector transformant. Although the amounts of VEGF secreted from two HeLa transformants differed greatly, MV833 completely inhibited the growth of both tumors. Moreover, the growth of the other 25 human tumor cell lines transplanted into nude mice was also strongly suppressed by MV833. Neither the amount of VEGF secreted from each tumor cell line in vitro nor the expression of VEGF receptor correlated with the antitumor activity of MV833. MV833, administered when tumor volumes reached 400 mm3, completely inhibited the growth of some tumor lines. The results show VEGF to be a critical angiogenic factor for many tumors. VEGF—neutralizing antibody could be applicable as an antitumor agent for a wide range of tumors.

Keywords: VEGF, Monoclonal antibody, Antitumor activity, Nude mice, Xenograft

Full Text

The Full Text of this article is available as a PDF (2.1 MB).

REFERENCES

  • 1. ) Folkman , J.Tumor angiogenesis . Adv. Cancer Res. , 43 , 175 – 203 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Folkman , J.What is the evidence that tumors are angiogenesis dependent ?. J. Natl. Cancer Inst. , 82 , 4 – 6 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Folkman , J. and Klagsbrun , M.Angiogenic factors . Science , 235 , 442 – 447 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Klagsbrun , M. and D'Amore , P. A.Regulators of angiogenesis . Annu. Rev. Physiol. , 53 , 217 – 239 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Folkman , J. and Shing , Y.Angiogenesis . J. Biol. Chem. , 267 , 10931 – 10934 ( 1992. ). [PubMed] [Google Scholar]
  • 6. ) Leung , D. W. , Cachianes , G. , Kuang , W.‐J. , Goeddel , D. V. and Ferrara , N.Vascular endothelial growth factor is a secreted angiogenic mitogen . Science , 246 , 1306 – 1309 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Senger , D. R. , Galli , S. J. , Dvorak , A. M. , Perruzzi , C. A. , Harvey , V. S. and Dvorak , H. F.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid . Science , 219 , 983 – 985 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Plöuet , J. , Schilling , J. and Gospodarowicz , D.Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells . EMBO J. , 8 , 3801 – 3806 ( 1989. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ) Plate , K. H. , Breier , G. , Weich , H. A. and Risau , W.Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo . Nature , 359 , 845 – 848 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Takano , S. , Yoshii , Y. , Kondo , S. , Suzuki , H. , Maruno , T. , Shirai , S. and Nose , T.Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patient . Cancer Res. , 56 , 2185 – 2190 ( 1996. ). [PubMed] [Google Scholar]
  • 11. ) Mattern , J. , Koomagi , R. and Volm , M.Vascular endothelial growth factor expression and angiogenesis in non–small cell lung carcinomas . Int. J. Oncol. , 6 , 1059 – 1062 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Toi , M. , Inada , K. , Suzuki , H. and Tominaga , T.Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression . Breast Cancer Res. Treat. , 36 , 193 – 204 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Takahashi , Y. , Kitadai , Y. , Bucana , C. D. , Cleary , K. R. and Ellis , L. M.Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer . Cancer Res. , 55 , 3964 – 3968 ( 1995. ). [PubMed] [Google Scholar]
  • 14. ) Takahashi , A. , Sasaki , H. , Kim , S. J. , Tobisu , K. , Kakizoe , T. , Tsukamoto , T. , Kumamoto , Y. , Sugimura , T. and Terada , M.Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis . Cancer Res. , 54 , 4233 – 4237 ( 1994. ). [PubMed] [Google Scholar]
  • 15. ) Guidi , A. J. , Abu‐Jawdeh , G. , Berse , B. , Jakeman , R. W. , Tognazzi , K. , Dvorak , H. F. and Brown , L. F.Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia . J. Natl. Cancer Inst. , 87 , 1237 – 1245 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Mise , M. , Arai , S. , Higashituji , H. , Furutani , M. , Niwano , M. , Harada , T. , Ishigami , S. , Toda , Y. , Nakayama , H. , Fukumoto , M. , Fujita , J. and Imamura , M.Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor . Hepatology , 23 , 455 – 464 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 17. ) Boocock , C. A. , Charnock‐Jones , D. S. , Sharkey , A. M. , McLaren , J. , Barker , P. J. , Wright , K. A. , Twentyman , P. R. and Smith , S. K.Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma . J. Natl. Cancer Inst. , 87 , 506 – 516 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Kondo , S. , Asano , M. and Suzuki , H.Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody . Biochem. Biophys. Res. Commun. , 194 , 1234 – 1241 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Kondo , S. , Asano , M. , Matsuo , K. , Ohmori , I. and Suzuki , H.Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor–bearing mice and cancer patients . Biochim. Biophys. Acta , 1221 , 211 – 214 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Yamamoto , Y. , Toi , M. , Kondo , S. , Matsumoto , T. , Suzuki , H. , Kitamura , M. , Tsuruta , K. , Taniguchi , T. , Okamoto , A. , Mori , T. , Yoshida , M. , Ikeda , T. and Tominaga , T.Concentration of vascular endothelial growth factor in the sera of normal control and cancer patients . Clin. Cancer Res. , 2 , 821 – 826 ( 1996. ). [PubMed] [Google Scholar]
  • 21. ) Yeo , K.‐T. , Wang , H. H. , Nagy , J. A. , Sioussat , T. M. , Ledbetter , S. R. , Hoogewerf , A. J. , Zhou , Y. , Masse , E. M. , Senger , D. R. , Dvorak , H. F. and Yeo , T.‐K.Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions . Cancer Res. , 53 , 2912 – 2918 ( 1993. ). [PubMed] [Google Scholar]
  • 22. ) Asano , M. , Yukita , A. , Matsumoto , T. , Kondo , S. and Suzuki , H.Inhibition of tumor growth and metastasis by a neutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121 Cancer Res. , 55 , 5296 , 5301 – 1995 . [PubMed] [Google Scholar]
  • 23. ) Asano , M. , Yukita , A. , Matsumoto , T. , Matsuo , K. , Kondo , S. and Suzuki , H.Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121) . Hybridoma , 14 , 475 – 480 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Asano , M. , Yukita , A. , Matsumoto , H. , Hanatani , M. and Suzuki , H.An anti‐human VEGF monoclonal antibody, MV833, that exhibits potent anti‐tumor activity in vivo . Hybridoma , 17 , 185 – 190 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Kondo , S. , Matsumoto , T. , Yokoyama , Y. , Ohmori , I. and Suzuki , H.The shortest isoform of human vascular endothelial growth factor/vascular permeability factor (VEGF/VPF121) produced by Saccharomyces cerevisiae promotes both angiogenesis and vascular permeability . Biochim. Biophys. Acta , 1243 , 195 – 202 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Kim , K. J. , Li , B. , Winer , J. , Armanini , M. , Gillett , N. , Phillips , H. S. and Ferrara , N.Inhibition of vascular endothelial growth factor–induced angiogenesis suppresses tumour growth in vivo . Nature , 362 , 841 – 844 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) de Vries , C. , Escobedo , J. A. , Ueno , H. , Houck , K. , Ferrara , N. and Williams , L. T.The fms‐like tyrosine kinase, a receptor for vascular endothelial growth factor . Science , 255 , 989 – 991 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Terman , B. I. , Vermazen , M. D. , Carrion , M. E. , Dimitrov , D. , Armellino , D. T. , Gospodsrowicz , D. and Bohlen , P.Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor . Biochem. Biophys. Res. Commun. , 187 , 1579 – 1585 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Waltenberger , J. , Claesson‐Welsh , L. , Siegbahn , A. , Shibuya , M. and Heldin , C.H.Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor . J. Biol. Chem. , 269 , 26988 – 26995 ( 1994. ). [PubMed] [Google Scholar]
  • 30. ) Gitay‐Goren , H. , Halaban , R. and Neufeld , G.Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptor . Biochem. Biophys. Res. Commun. , 190 , 702 – 709 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 31. ) Katoh , O. , Tauchi , H. , Kawaishi , K. , Kimura , A. and Satow , Y.Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation . Cancer Res. , 55 , 5687 – 5692 ( 1995. ). [PubMed] [Google Scholar]
  • 32. ) Soker , S. , Takashima , S. , Miao , H. Q. , Neufeld , G. and Klagsbrun , M.Neuropilin‐1 is expressed by endothelial and tumor cells as an isoform‐specific receptor for vascular endothelial growth factor . Cell , 92 , 735 – 745 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 33. ) Warren , R. S. , Yuan , H. , Matil , M. R. , Gillett , N. A. and Ferrara , N.Regulation of vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental metastasis . J. Clin. Invest. , 95 , 1789 – 1797 ( 1995. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. ) Melnyk , O. , Shuman , M. A. and Kim , K. J.Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth . Cancer Res. , 56 , 921 – 924 ( 1996. ). [PubMed] [Google Scholar]
  • 35. ) Millauer , B. , Shawver , L. K. , Plate , K. H. , Risau , W. and Ullrich , A.Glioblastoma growth inhibited in vivo by a dominant‐negative Flk‐1 mutant . Nature , 367 , 576 – 579 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Millauer , B. , Longhi , M. P. , Plate , K. H. , Shawver , L. K. , Risau , W. , Ullrich , A. and Strawn , L. M.Dominant‐negative inhibition of Flk‐1 suppresses the growth of many tumor types in vivo . Cancer Res , 56 , 1615 – 1620 ( 1996. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES